June 1-5th,2007 / Chicago, USA Relevance of a medicosurgical strategy combining cetuximab and chronomodulated chemotherapy with metastases resection as 3rd line treatment for patients with metastatic colorectal cancer. Karaboue A., Bouchahda M., Adam A., Innominato I., Bralet M.P., Moreau T., Hauteville D., Guettier C., Levi F. J Clin Oncol 2007: 25 (18), suppl 14505.
lire la suite
May 30th – June 3rd, 2008 / Chicago, USA
May 30th - June 3rd, 2008 / Chicago, USA Relevance of circadian coordination for the outcome of cancer patients. Lévi F., Parganiha A., Innominato P.F., Karaboué A., Poncet A., Moreau T., Garufi C., Focan C., Coudert B., and Georg B., for the ARTBC Chronotherapy Group. J Clin Oncol 2008: 26 (15) suppl 15043. Efficacy and…
lire la suite
June 4-8th, Chicago, 2010 / Chicago, USA
June 4-8th, Chicago, 2010 / Chicago, USA Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer. A European multicenter phase II trial. Levi F., Bouchahda M., Ducreux M., Karaboué A., Focan C. N. J., Rougier P., Innominato P., Smith D., Awad…
lire la suite
June 3– 7th, 2011 / Chicago, USA
June 3– 7th, 2011 / Chicago, USA Pharmacokinetic-pharmacodynamic analysis of hepatic artery infusion of three-drug chronomodulated chemotherapy and intravenous cetuximab in patients with liver metastases from colorectal cancer registered in OPTILIV, a european multicenter phase II trial. F. Levi, A. Karaboué, M. C. Etienne-Grimaldi, E. Chatelut, P. F. Innominato, G. Paintaud, P. oukakos, R. Adam,…
lire la suite
- 1
- 2